Maraviroc

Drugs of Today

Volumn 43, Issue 11, 2007, Pages 749-758

  Fadel, Hind ^a   Temesgen, Zelalem ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APLAVIROC; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DELAVIRDINE; EFAVIRENZ; ENFUVIRTIDE; KETOCONAZOLE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ASTHENIA; BLURRED VISION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; DYSURIA; FATIGUE; FEVER; FLATULENCE; FOOD; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; HEADACHE; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INFLUENZA; LIVER DISEASE; LYMPHOMA; MONOTHERAPY; MYALGIA; NAUSEA; NONHUMAN; OCULAR HYPEREMIA; ORTHOSTATIC HYPOTENSION; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; CONTROLLED CLINICAL TRIALS AS TOPIC; CYCLOHEXANES; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOOD-DRUG INTERACTIONS; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; TRIAZOLES;

EID: 38349019887     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.11.1131763     Document Type: Review

References (32)

1. Palella, F.J. Jr., Delaney, K.M., Moorman, A.C. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338: 853-60.
2. Temesgen, Z., Warnke, D., Kasten, M.J. Current status of antiretroviral therapy. Expert Opin Pharmacother 2006, 7: 1541-54.
3. Moore, J.P., Doms, R.W. The entry of entry inhibitors: A fusion of science and medicine. Proc Natl Acad Sci USA 2003, 100 :10598-602
4. Dragic, T., Litwin, V., Allaway, G.P. et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381: 667-73.
5. Deng, H., Liu, R., Ellmeier, W. et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381: 661-6.
6. Philpott, S.M. HIV-1 coreceptor usage, transmission, and disease progression. Curr HIV Res 2003, 1:217-27.
7. Liu, R., Paxton, W.A., Choe, S. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86: 367-77.
8. Eugen-Olsen, J., Iversen, A.K., Garred, P. et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997, 11: 305-10.
9. Dorr, P., Westby, M., Dobbs, S. et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005, 49: 4721-32.
10. Pullen, S., Sale, H., Napier, C. et al. Maraviroc (UK-427,857) is a slowly reversible antagonist at the human CCR5 in a CRE luciferase reporter gene assay. 13th Conference on Retroviruses and Opportunistic Infections, Denver 2006, Abst 504.
11. Watson, C., Jenkinson, S., Kazmierski, W., Kenakin, T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 2005, 67: 1268-82.
12. Walker, D.K., Abel, S., Comby, P., Muirhead, G.J., Nedderman, A.N., Smith, D.A. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 2005, 33: 587-95.
13. Napier, C., Dorr, P., Gladue, R. The preclinical pharmacokinetics and safety pharmacology of the anti-HIV CCR5 antagonist, UK-427, 57. 10th Conference on Retroviruses and Opportunistic Infections, Boston 2003, Abst. 546.
14. Abel, S., Van der Ryst, E., Muirhead, G.J., Rosario, M.C., Edgington, A., Weissgerber, G. Pharmacokinetics of single and multiple doses of UK-427,857 - a novel CCR5 antagonist - in healthy volunteers. 10th Conference on Retroviruses and Opportunistic Infections, Boston 2003, Abst. 547.
15. an der Ryst, E., Fatkenheuer, G., Pozniak, A. et al. Evaluation of dosing frequency and food effect on viral load reduction during short-term monotherapy with UK-427,857, a novel CCR5 antagonist. 15th International AIDS Conference, Bangkok 2004, Abst. TuPeB4489.
16. Abel, S., Whitlock, L., Ridgeway, C. et al. Effect of UK-427,857 on the pharmacokinetics of oral contraceptive steroids, and the pharmacokinetics of UK-427,857 in healthy young women. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago 2003, Abst.
17. Abel, S., Russell, D., Ridgeway, C. et al. Effect of CCR5 antagonist UK-427,857 on the pharmacokinetics of CYP3A4 substrates in healthy volunteers. 5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome 2004, Abst.
18. Muirhead, G., Abel, S., Hackman, F. et al. Effect of maraviroc (UK-427,857) on the pharmacokinetics of 3TC/AZT (combivir) in healthy volunteers. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec City 2005, Abst.
19. Muirhead, G., Russell, D., Abel, S. et al. An investigation of the effects of tenofovir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857. 7th International Congress on Drug Therapy of HIV Infection, Glasgow 2004, Abst.
20. Muirhead, G., Pozniak, A.L., Gazzard, B. et al. A novel probe drug interaction study to investigate the effect of selected ARV combinations on the pharmacokinetics of a single oral dose of maraviroc (UK-427,857) in HIV+ subjects. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec City, Abst. 31.
21. Muirhead, G., Ridgway, C., Leahy, D., Mills, C., Van der Merwe, R., Russell, D. A study to investigate the combined co-administration of P450 CYP3A4 inhibitors and inducers on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857. 7th International Congress on Drug Therapy of HIV Infection, Glasgow 2004, Abst. P284.
22. Muirhead, G., Abel, S., Russell, D. et al. An investigation of the effects of atazanavir and ritonavir-boosted atazanavir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857. 7th International Congress on Drug Therapy of HIV Infection, Glasgow 2004, Abst.
23. Saag, M., Ive, P., Heera, J. et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: Week 48 results of the MERIT study. In: Program and abstracts 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention: July 22-25, 2007; Sydney, Australia, Abstr. WESS104.
24. Abel, S., Taylor-Worth, R., Ridgway, C. et al. Effect of boosted tipranavir on the pharmacokinetics of maraviroc (UK-427,857) in healthy volunteers. 10th European AIDS Conference, Dublin 2005, Abst. LBPE4.3/15.
25. Fatkenheuer, G., Pozniak, A.L., Johnson, M.A. et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005, 11: 1170-2.
26. Lalezari, J., Goodrich, J., DeJesus, E. et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles 2007, Abst. 104bLB.
27. Nelson, M., Fatkenheuer, G., Konourina, I. et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles 2007, Abst. 104aLB.
28. Mayer, H., Van der Ryst, E., Saag, M. et al. Safety and efficacy of maraviroc, a novel CCR5 antagonist, when used in combination with optimized background therapy for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial. 16th International AIDS Conference, Toronto 2006, Abst. THLB0215.
29. McHale, M., Abel, S., Russell, D., Gallagher, J., Van der Ryst, E. Overview of phase 1 and 2a safety and efficacy data of maraviroc (UK-427,857). 3rd International AIDS Conference, Rio de Janeiro 2005, Abst. TuOa0204.
30. Westby, M., Smith-Burchnell, C., Mori, J. et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains re sistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007, 81: 2359-71.
31. Westby, M., Lewis, M., Whitcomb, J. et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006, 80: 4909-20.
32. Glass, W.G., McDermott, D.H., Lim, J.K. et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006, 203: 35-40.